MSLN and ovarian carcinoma: To further enhance TME-dependent CD40 activation while minimizing systemic toxicity, a first-in-class mesothelin–CD40 bispecific antibody was recently engineered and tested in patients with tumors expressing high levels of mesothelin, such as PM and ovarian cancer.